AM
Alexander Mayweg
Managing Director at Versant Ventures
Basel, Basel
Overview
Alexander Mayweg is the Managing Director at Versant Ventures, with a significant background in drug discovery and medicinal chemistry. His career highlights include founding Black Diamond Therapeutics as CSO and serving as President and CSO at Ridgeline Therapeutics.
Mayweg has a strong track record of success in leadership roles within the pharmaceutical industry, notably as the Global Head of Medicinal Chemistry at Roche and as a board member for various biotech companies.
Work Experience
Managing Director
2020 - Current
Partner
2018 - 2020
Venture Partner
2017 - 2017
Entrepreneur in Residence
2016 - 2016
Versant Ventures caters to the healthcare sector with early and later stage venture, private equity, and debt financing investments.
President of the Board of Directors
2022
President of the Board of Directors
2021
President of the Board of Directors
2022
President of the Board of Directors
2022
Chairman of the Board
2022
Board Member
2017
President and CSO
2017
Ridgeline Therapeutics is emerging biotechnology developing new drugs to cure Type 2 diabetes, muscular, age-related muscle degeneration.
Board Director
2018
Board Director
2018 - 2024
Education
Post Doc
2001 - 2003
D.Phil.
1998 - 2001
B.Sc.
1994 - 1998
Abitur (IB equivalent)
1989 - 1994